Editor-in-Chief & Deputy Editor 2019-2021

 

Editor-in-Chief:

Nicolas LANTHIER

 

Deputy Editor:

Tim VANUYTSEL

 

 

Sponsors & Partners



Acta Gastroenterologica Belgica is supported by grants from its major sponsors

 

Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma

 

 

 

 

 

 

Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies


 

 

 

 

 

SRBGE

 

Stepwise minimization of the immunosuppressive therapy in pediatric liver transplantation. A conceptual approach towards operational tolerance (*)Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation

Strategies targeting tumor necrosis factor in Crohn's disease

Price: €10,00








(Acta gastroenterol. belg., 2001, 64, 170-172)

April-June Volume 64, fasc. 2

Strategies targeting tumor necrosis factor in Crohn's disease

W. J. Sandborn. Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, U.S.A.

Ibmor necrosis factor plays an important role in mediating the inflammation of Crohn's disease. Strategies aimed at reducing tumor necrosis factor in patients with Crohn's disease include the mouse/human chimeric monoclonal antibody infliximab, the humanized monoclonal antibody CDP571, the human recombinant tumor necrosis factor receptor fusion protein etanercept, and the small molecule thalidomide. Infliximab is effective for treating active Crohn's disease, maintaining remission, and closing fistulas. Side effects occurring in patients treated with infliximab include human anti-chimeric antibodies, infusion reactions, formation of autoantibodies, and rarely drug induced lupus. CDP571 is effective for treating active Crohn's disease, steroid sparing, and possibly for closing fistulas and maintaining remission. Side effects occurring in patients treated with CDP571 include anti-idiotype antibodies, infusion reactions, and formation of autoantibodies. Pilot studies have suggested that etanercept and thalidomide may also be beneficial. Anti-tumor necrosis factor therapies are effective for the treatment for Crohn's disease.